TACR1 and Lyme disease: Consistent with our previous studies using frontal cortex explants and isolated DRG cells [12], treatment with the NK-1R antagonist, aprepitant, was able to significantly attenuate the transcription of inflammatory mediators in our in vivo NHP model of Lyme neuroborreliosis.